Table 1.
Prior probability distributions for prevalence of antimicrobial resistance and for sensitivities and specificities of susceptibility tests
| Beta distribution parameters (a, b)* | Mode (%) | 95% PI | ||
|---|---|---|---|---|
| Resistance prevalence | ||||
| Sample set 1 | ||||
| E. coli | ||||
| Ampicillin | (1·3, 6·0) | 6·5 | 1·2–50·9 | |
| Ceftiofur | (1·0, 7·0) | 0·4 | 0·4–41·3 | |
| Streptomycin | (2·2, 4·0) | 27·8 | 6·2–72·8 | |
| Sulfisoxazole | (2·2, 2·1) | 52·9 | 11·3–90·5 | |
| Tetracycline | (2·9, 3·0) | 48·7 | 13·8–85·0 | |
| TMP-SMX | (1·1, 4·5) | 2·8 | 0·8–57·3 | |
| M. haemolytica | ||||
| Ampicillin | (1·8, 2·4) | 37·5 | 6·7–85·7 | |
| Tetracycline | (1·7, 2·0) | 40·1 | 6·6–88·9 | |
| Sample set 2 | ||||
| E. coli | ||||
| Ampicillin | (1·2, 6·0) | 3·5 | 0·1–48·7 | |
| Ceftiofur | (1·0, 7·0) | 0·7 | 0·4–41·6 | |
| Streptomycin | (2·2, 4·0) | 29·3 | 6·8–73·4 | |
| Sulfisoxazole | (1·8, 1·9) | 47·1 | 7·9–90·7 | |
| Tetracycline | (3·1, 2·6) | 56·4 | 16·8–88·7 | |
| TMP-SMX | (1·0, 2·2) | 0·8 | 1·2–80·9 | |
| M. haemolytica | ||||
| Ampicillin | (1·8, 2·2) | 39·5 | 6·7–87·8 | |
| Tetracycline | (1·6, 1·9) | 43·0 | 6·5–90·5 | |
| Disk diffusion | Sensitivity | (2·0, 1·1) | 67·9 | 14·8–98·2 |
| Specificity | (2·0, 1·1) | 67·9 | 14·8–98·2 | |
| Broth microdilution | Conditional sensitivity | (4·8, 1·2) | 83·3 | 43·1–99·0 |
| Conditional specificity | (4·8, 1·2) | 83·3 | 43·1–99·0 | |
PI, Probability interval; TMP-SMX, trimethoprim-sulfamethoxazole.
*
Parameters for the beta distributions were truncated to one significant digit for presentation in this table.